Condition (MeSH)
Cryopyrin-Associated Periodic Syndromes
ClinicalTrials.gov lists 35 trials for Cryopyrin-Associated Periodic Syndromes or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 10.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
35 of the 35 trials are tagged with Cryopyrin-Associated Periodic Syndromes itself; the rest are tagged with a narrower condition beneath it.
When did Cryopyrin-Associated Periodic Syndromes trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 1 |
Showing 10 of 20 earlier years.
No forecast is made for this condition: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Cryopyrin-Associated Periodic Syndromes trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 2 |
| Phase 2 | 9 |
| Phase 3 | 9 |
| Not applicable | 3 |
| Observational | 7 |
How many Cryopyrin-Associated Periodic Syndromes trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 4 |
| Completed | 22 |
| Terminated | 5 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Cryopyrin-Associated Periodic Syndromes trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 10 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 3 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 3 |
| Handok Inc. | 2 |
| Novartis | 2 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Cryopyrin-Associated Periodic Syndromes? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Rilonacept | 3 |
| 124I AT-01 | 1 |
| ATI-450 | 1 |
| Tranilast | 1 |
| Gevokizumab | 1 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Canakinumab, ACZ885 | 10 |
| Anakinra alone (stages 2b/3) | 4 |
| HL2351 | 2 |
| VTX2735 | 1 |
| Saliva sampling | 1 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Cryopyrin-Associated Periodic Syndromes trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Headache | 6 | 2 |
| Arthritis | 4 | 3 |
| Pneumonia | 4 | 2 |
| Abdominal pain | 3 | 2 |
| Lung infection | 3 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Cryopyrin-Associated Periodic Syndromes? (22)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry. | RMD open | 2021 | Yes |
| Efficacy and safety of ucha-shinki-hwan on korean patients with cold hypersensitivity in the hands and feet: Study protocol clinical trial (SPIRIT Compliant). | Medicine | 2020 | Yes |
| Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger. | Arthritis & rheumatology (Hoboken, N.J.) | 2019 | Yes |
| Validity and reliability of the Turkish version of the Cold Intolerance Symptom Severity Questionnaire | Turkish journal of medical sciences | 2019 | Yes |
| The efficacy and safety of Sipjeondaebo-tang in Korean patients with cold hypersensitivity in the hands and feet: a protocol for a pilot, randomized, double-blind, placebo-controlled, parallel-group clinical trial. | Trials | 2019 | Yes |
Showing 5 of 22 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| NLRP3-associated autoinflammatory disease | Point prevalence | 1-9 / 1 000 000 | France | Not stated | Unspecified |
| NLRP3-associated autoinflammatory disease | Point prevalence | 1-9 / 1 000 000 | France | Not stated | Exact |
| NLRP3-associated autoinflammatory disease | Point prevalence | 1-9 / 1 000 000 | France | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| NLRP3-associated autoinflammatory disease | 208650 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| NLRP3-associated autoinflammatory disease | 208650 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.